Investor Overview

Corporate Profile

vTv Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

Presentations

Date Title
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientifi
HIGH POINT, N.C. , May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.  (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive therapy in type 1 diabetes will be presented virtually at the American Diabetes Association’s 80th
View HTML
Toggle Summary vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format
HIGH POINT, N.C. , May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-only meeting that will be held via live audio webcast due to the public health and safety concerns
View HTML
Toggle Summary vTv Therapeutics Announces 2020 First Quarter Financial Results and Update
HIGH POINT, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020 , and provided an update on recent clinical achievements. “In spite of the challenges presented by the COVID-19 pandemic, we are
View HTML
Toggle Summary vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range HIGH POINT, N.C. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Webcasts
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Copyright West LLC. Minimum 15 minutes delayed.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.